News & Updates

Show Multimedia Only

Children with ALL suffer drug therapy problems

30 Jul 2025

Drug therapy problems (DTPs), such as adverse drug reactions (ADRs), remain highly prevalent in children with acute lymphoblastic leukaemia (ALL), a study has found.

Children with ALL suffer drug therapy problems

30 Jul 2025

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025 by

Radiologic imaging of high-risk cutaneous squamous cell carcinoma (sSCC) tumours displays unforeseen results such as local invasion and nodal metastasis, which result in changes in management in nearly half of these cases, reveals a study.

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025

COVID-19 ups risk of hospitalization, treatment disruptions, death among cancer patients

26 Jul 2025

COVID-19 appears to have adverse consequences for patients with cancer, including increased hospitalization, treatment disruption, and death, according to a study.

COVID-19 ups risk of hospitalization, treatment disruptions, death among cancer patients

26 Jul 2025

How do parents perceive physical activity in children with cancer?

24 Jul 2025 by

The role of the family is critical to the encouragement of physical activity (PA) among childhood cancer survivors (CCS), according to a Singapore study. Apart from individuals and families, the community and society can also influence participation in PA.

How do parents perceive physical activity in children with cancer?

24 Jul 2025

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

24 Jul 2025

A recent phase III trial of NUC-1031/cisplatin has been terminated early due to ineffectiveness as first-line treatment for advanced biliary tract cancer (BTC).

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

24 Jul 2025

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

24 Jul 2025 by

A post-hoc analysis of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC) has found that while durvalumab demonstrated an overall survival (OS) benefit vs placebo irrespective of immune-mediated adverse events (imAEs), the improvement in OS was numerically greater among patients who experienced imAEs.

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

24 Jul 2025

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

24 Jul 2025 by

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) in East Asian patients with persistent, recurrent or metastatic cervical cancer, according to an exploratory analysis of the final results from the phase III KEYNOTE-826 trial.

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

24 Jul 2025

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025 by

Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

New drug applications approved by US FDA as of 1-15 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Children with ALL suffer drug therapy problems

Children with ALL suffer drug therapy problems

Is radiologic imaging necessary in cutaneous SCC?

Is radiologic imaging necessary in cutaneous SCC?

COVID-19 ups risk of hospitalization, treatment disruptions, death among cancer patients

COVID-19 ups risk of hospitalization, treatment disruptions, death among cancer patients

How do parents perceive physical activity in children with cancer?

How do parents perceive physical activity in children with cancer?

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

First-line NUC-1031/cisplatin trial for advanced BTC cut short due to futility

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

TOPAZ-1: Greater numeric improvement in OS among biliary tract cancer patients with immune-mediated AEs

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer

COVID-19 booster shots confer protection against severe disease in cancer patients

COVID-19 booster shots confer protection against severe disease in cancer patients

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

Original New Drug Application Approvals by US FDA (16-30 June 2025)